Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Zacks Investment Research

08 Jul 2026, 22:51 UTC · 3h ago

Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

3 claims · each scored for market impact

What matters in this story

1
Recursion Pharmaceuticals (RXRX) is currently assigned a Zacks Rank of #2 (Buy). — A 'Buy' rating from a recognized research provider typically signals positive sentiment and potential price appreciation for the specific equity.
+0.40
2
The consensus revenue estimate for Recursion Pharmaceuticals' upcoming quarter is $11.99 million, representing a 37.64% decline year-over-year. — A significant double-digit drop in revenue suggests weakening top-line growth or scaling challenges.
-0.30
3
The forecasted EPS for Recursion Pharmaceuticals' next quarter is -$0.25, which is a 39.02% improvement over the prior year. — While still loss-making, the narrowing of losses indicates improving operational efficiency or cost management.
+0.20